[EN] 4-PIPERAZINYL-PYRIMIDINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR<br/>[FR] COMPOSÉS DE 4-PIPÉRAZINYLPYRIMIDINE CONVENANT POUR TRAITER DES TROUBLES QUI RÉPONDENT À UNE MODULATION DU RÉCEPTEUR D3 DE LA DOPAMINE
申请人:ABBOTT GMBH & CO KG
公开号:WO2006015842A1
公开(公告)日:2006-02-16
The present invention relates to novel 4-piperazinylpyrimidine compounds. The compounds possess valuable therapeutic properties and are suitable, in particular, for treating diseases that respond to modulation of the dopamine D3 receptor. The 4 piperzinylpyrimidine compounds have the general formula (I), wherein Ar, X, A, R1 and R1a are as defined in the claims.
4-PIPERAZINYL-PYRIMIDINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D<sb>3</sb> RECEPTOR
申请人:Abbott GmbH & Co. KG
公开号:EP1778684A1
公开(公告)日:2007-05-02
Film-Shaped Medicament for Oral Administration Containing Estriol
申请人:Moormann Joachim
公开号:US20070243217A1
公开(公告)日:2007-10-18
Film-shaped medicaments administered orally, particularly buccally, for treating climacteric complaints. The medicaments contain estriol and/or at least one pharmacologically acceptable ester of estriol, either alone or in combination with at least one gestagen.
ESTRIOL FORMULATIONS
申请人:Shaked Ze'ev
公开号:US20110250274A1
公开(公告)日:2011-10-13
Disclosed herein are oral dosage forms and methods of their use, in particular oral dosage systems for the delivery of estriol compounds. Embodiments described herein relate to rapidly disintegrating oral dosage formulations that disintegrate in the saliva of the buccal and/or sublingual and/or esophageal cavity. Oral dosage forms described herein relate to stabilized amorphous and nanocrystalline forms of the active ingredients of the formulations.